Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits growth of cancer cells including non-small cell lung cancer (NSCLC). Clinically, use of thiazolidinediones, which are pharmacological activators of PPARγ is associated with a lower risk of developing lung cancer. However, th...
Main Authors: | Howard Li, Amber L Sorenson, Joanna Poczobutt, Jay Amin, Teresa Joyal, Timothy Sullivan, Joseph T Crossno, Mary C M Weiser-Evans, Raphael A Nemenoff |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3228753?pdf=render |
Similar Items
-
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword
by: Howard Li, et al.
Published: (2012-01-01) -
Peroxisome Proliferator-Activated Receptor-γ Inhibits Transformed Growth of Non-Small Cell Lung Cancer Cells through Selective Suppression of Snail
by: Rashmi Choudhary, et al.
Published: (2010-03-01) -
Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-γ Ligands in Lung Cancer
by: Raphael A. Nemenoff, et al.
Published: (2008-01-01) -
Lack of PPARγ in myeloid cells confers resistance to Listeria monocytogenes infection.
by: Zeinab Abdullah, et al.
Published: (2012-01-01) -
Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment.
by: Joanna M Poczobutt, et al.
Published: (2013-01-01)